Filed Sept. 11, 2023

Serial No. 98173706

Examining Attorney BRENDAN SMITH

Class house mark for a full line of biologic, biosimilar, and pharmaceutical preparations; biologics; biosimilars; pharmaceuticals; biologic, biosimilar, and pharmaceutical preparations; biologic, biosimilar, and pharmaceutical products; anti-TNF alpha antibodies for medical purposes; monoclonal antibodies for medical purposes; anti-inflammatories; anti-inflammatory biologic, biosimilar, and pharmaceutical preparations, namely, anti-inflammatory preparations; biologic, biosimilar, and pharmaceutical preparations for the treatment of lung diseases and disorders; biologic, biosimilar, and pharmaceutical preparations for the treatment of inflammatory disorders; biologic, biosimilar, and pharmaceutical preparations for the treatment of pulmonary sarcoidosis; biologic, biosimilar, and pharmaceutical preparations for the treatment of sarcoidosis; biologic, biosimilar, and pharmaceutical preparations to reduce or prevent granulomas; biologic, biosimilar, and pharmaceutical preparations to reduce or prevent fibrosis; biologic, biosimilar, and pharmaceutical preparations, namely, biopharmaceutical preparations based on human monoclonal antibodies for the treatment of inflammatory diseases and disorders; self-replicating mRNA; pharmaceutical preparations containing self-replicating mRNA; pharmaceutical preparations containing self-replicating mRNA for the treatment of lung diseases and disorders, inflammatory disorders, pulmonary sarcoidosis, sarcoidosis; pharmaceutical preparations containing self-replicating mRNA to reduce or prevent granulomas; pharmaceutical preparations containing self-replicating mRNA to reduce or prevent fibrosis; 005; 006; 018; 044; 046; 051; 052; 100; 101; 100; 101